Recently, the China National Medical Products Administration (NMPA) approved a new indication for Bireociclib, a Class 1 innovative drug independently developed by Xuanzhu Biopharmaceutical. The new indication is for use in combination with an aromatase inhibitor as an initial endocrine therapy for patients with HR+/HER2- advanced breast cancer. This approval marks Bireociclib as the first and only drug in its class in China to cover the full course of treatment for HR+/HER2- advanced breast cancer—including first-line, second-line, and later-line therapies—offering a new treatment option for patients worldwide.
If you or your loved ones are seeking better breast cancer treatment options, please feel free to contact the International Department of Beijing South Region Oncology Hospital:
- Phone: 400-880-3716
- WeChat: 17801183037
- Email ①: 100085_010@163.com
- Email ②: myimmnet@163.com
—
**From Second-Line to First-Line: The “Full-Course” Breakthrough of Bireociclib**
Bireociclib is a novel CDK2/4/6 inhibitor. It was previously approved for use in combination with fulvestrant for advanced breast cancer that has progressed after endocrine therapy, as well as a monotherapy for patients with refractory disease. The approval of this new indication advances its use to first-line endocrine therapy, truly achieving full coverage from initial treatment to later-line rescue therapy.
This approval is based on the interim analysis results of the BRIGHT-3 study. The study showed that the median progression-free survival (PFS) for the Bireociclib plus AI group has not yet been reached, indicating a remarkably durable efficacy; in comparison, the PFS for the control group was 18.4 months. Even more encouragingly, the 2-year PFS rate in the Bireociclib group exceeded 60%, and the objective response rate (ORR) reached 63.5%, climbing to 67.6% in patients with measurable lesions. These data indicate that Bireociclib currently demonstrates the most superior efficacy among similar drugs.
**More Sophisticated Design: Multi-Target Synergy Balancing Efficacy and Safety**
The uniqueness of Bireociclib lies in its multi-target synergistic mechanism of action. As a novel CDK2/4/6 inhibitor, it not only potently inhibits CDK4 and CDK6 but also simultaneously inhibits CDK2 and CDK9.
- **Delaying Drug Resistance:** Activation of CDK2 is one of the key mechanisms of resistance to CDK4/6 inhibitors. By simultaneously inhibiting CDK2, Bireociclib can more thoroughly block the proliferation pathways of tumor cells, thereby delaying the onset of drug resistance from the source.
- **Lower Toxicity:** Hematological toxicities such as grade 3/4 neutropenia, commonly seen with traditional CDK4/6 inhibitors, are significantly reduced with Bireociclib treatment. This means patients can achieve better treatment tolerance, reducing treatment interruptions due to side effects, thereby ensuring the continuity of efficacy.
**Data Validates Strength: Comprehensive Success of the BRIGHT Study Series**
The excellent performance of Bireociclib is not an isolated case but is built upon a solid foundation of the BRIGHT study series:
- **BRIGHT-2 Study (Second-Line Treatment):** Bireociclib combined with fulvestrant achieved a median PFS of 17.5 months. In non-head-to-head comparisons, this data is the best-in-class.
- **BRIGHT-1 Study (Later-Line Monotherapy):** For heavily pre-treated, highly refractory advanced patients, Bireociclib monotherapy resulted in a median PFS of 11 months and a median overall survival (OS) of 29 months. This is also a global best-in-class data point, proving its potent efficacy in the most challenging patient populations.
**Why Choose the International Department of Beijing South Region Oncology Hospital?**
The International Department of Beijing South Region Oncology Hospital is dedicated to connecting global cutting-edge pharmaceutical innovation with top-tier Chinese clinical resources. As an innovative drug developed in China, the approval of Bireociclib not only benefits domestic patients but also offers new hope for international patients. Our International Department provides overseas patients with:
1. **Multidisciplinary Consultation:** Assessment of medical conditions and development of personalized plans by a team of leading experts in the breast cancer field.
2. **Access to Innovative Drugs:** Timely access to China’s newest approved anticancer drugs, including Bireociclib.
3. **Full-Process Service:** One-stop medical support, from initial consultation and treatment plan implementation to long-term follow-up.
4. **Language and Transportation Assistance:** Professional medical translation and dedicated access for international patients to address logistical concerns.
**Contact Us Now**
If you or your family members are battling HR+/HER2- advanced breast cancer and wish to learn whether Bireociclib could be a suitable treatment option, please contact the International Department of Beijing South Region Oncology Hospital immediately. Our professional team will provide you with detailed medical consultation and assistance for seeking medical care in China.
- ��� Phone: 400-880-3716
- ��� WeChat: 17801183037
- ��� Email: 100085_010@163.com or myimmnet@163.com
Post time: Mar-06-2026